体弱老年非ST段抬高型急性心肌梗死患者常规侵入性与保守策略效果比较:随机临床试验
这项多中心随机临床试验纳入167例年龄≥70岁、临床衰弱量表评分≥4分的NSTEMI患者,比较常规侵入性策略(冠状动脉造影及可行血运重建,n=84)与保守策略(药物治疗、复发缺血时造影,n=83)。主要终点为出院至1年的存活出院天数(DAOH),保守组312天(95%CI 289-335) vs 侵入组284天(95%CI 255-311),差异28天(95%CI -7至62),P=0.12;全因死亡HR 1.45(95%CI 0.74-2.85,P=0.28);主要复合终点亚分布HR 0.92(95%CI 0.54-1.57,P=0.78)。作者结论为常规侵入性策略无获益,推荐药物管理与密切观察。
要点
- 体弱(临床衰弱量表≥4分)老年(≥70岁)NSTEMI患者中,保守策略1年DAOH为312天(95%CI 289-335),侵入性策略为284天(95%CI 255-311),差异28天(95%CI -7至62),P=0.12,未达统计学显著。
- 全因死亡侵入组与保守组HR 1.45(95%CI 0.74-2.85,P=0.28),无统计学差异。
- 限制性平均生存时间分析显示侵入组较保守组生存时间缩短28天(95%CI -63至7天)。
- 缺血性心脏事件复合终点(心源性死亡、再梗死或出院后血运重建)亚分布HR 0.92(95%CI 0.54-1.57,P=0.78),无差异。
- 再入院中非心脏原因占56%,两组再入院次数及出院后住院天数无差异。
适用人群与场景
- 年龄≥70岁、临床衰弱量表评分≥4分、非ST段抬高型急性心肌梗死(NSTEMI)的老年患者。
诊断标准与关键阈值
- 衰弱定义:临床衰弱量表(Clinical Frailty Scale)评分≥4分。
- NSTEMI诊断由原文语境确定,原文未列出具体诊断标准。
处置流程与药物剂量
- 常规侵入性策略:冠状动脉造影,若可行则行血运重建(n=84)。
- 保守策略:药物治疗,仅在复发缺血时行冠状动脉造影(n=83)。
研究设计与关键结果
- 多中心随机临床试验,13家西班牙医院,2017年7月7日至2021年1月9日纳入167例患者;因COVID-19疫情在入组达计算样本量95%时提前终止。
- 平均(SD)年龄86(5)岁,平均(SD)临床衰弱量表评分5(1)。
- 主要终点DAOH:保守组312天(95%CI 289-335) vs 侵入组284天(95%CI 255-311),差异28天(95%CI -7至62),P=0.12。
- 按性别分层敏感性分析未显示差异。
- 全因死亡:HR 1.45(95%CI 0.74-2.85),P=0.28。
- 限制性平均生存时间分析:侵入组较保守组生存缩短28天(95%CI -63至7天)。
- 再入院中非心脏原因占56%;两组再入院次数及出院后住院天数无差异。
- 复合终点(心源性死亡、再梗死或出院后血运重建):亚分布HR 0.92(95%CI 0.54-1.57),P=0.78。
证据类型、等级与局限
- 证据类型:多中心随机临床试验。
- 局限:研究因COVID-19疫情在入组达计算样本量95%时提前终止;原文未报告其他局限性。
对床旁实践的改变
- 作者基于该试验结果推荐:对体弱老年NSTEMI患者采取药物管理与密切观察策略。
指南或共识出处
- 临床试验注册号:ClinicalTrials.gov NCT03208153。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: To our knowledge, no randomized clinical trial has compared the invasive and conservative strategies in frail, older patients with non-ST-segment elevation acute myocardial infarction (NSTEMI).
OBJECTIVE: To compare outcomes of invasive and conservative strategies in frail, older patients with NSTEMI at 1 year.
DESIGN, SETTING, AND PARTICIPANTS: This multicenter randomized clinical trial was conducted at 13 Spanish hospitals between July 7, 2017, and January 9, 2021, and included 167 older adult (≥70 years) patients with frailty (Clinical Frailty Scale score ≥4) and NSTEMI. Data analysis was performed from April 2022 to June 2022.
INTERVENTIONS: Patients were randomized to routine invasive (coronary angiography and revascularization if feasible; n = 84) or conservative (medical treatment with coronary angiography for recurrent ischemia; n = 83) strategy.
MAIN OUTCOMES AND MEASURES: The primary end point was the number of days alive and out of the hospital (DAOH) from discharge to 1 year. The coprimary end point was the composite of cardiac death, reinfarction, or postdischarge revascularization.
RESULTS: The study was prematurely stopped due to the COVID-19 pandemic when 95% of the calculated sample size had been enrolled. Among the 167 patients included, the mean (SD) age was 86 (5) years, and mean (SD) Clinical Frailty Scale score was 5 (1). While not statistically different, DAOH were about 1 month (28 days; 95% CI, -7 to 62) greater for patients managed conservatively (312 days; 95% CI, 289 to 335) vs patients managed invasively (284 days; 95% CI, 255 to 311; P = .12). A sensitivity analysis stratified by sex did not show differences. In addition, we found no differences in all-cause mortality (hazard ratio, 1.45; 95% CI, 0.74-2.85; P = .28). There was a 28-day shorter survival in the invasive vs conservatively managed group (95% CI, -63 to 7 days; restricted mean survival time analysis). Noncardiac reasons accounted for 56% of the readmissions. There were no differences in the number of readmissions or days spent in the hospital after discharge between groups. Neither were there differences in the coprimary end point of ischemic cardiac events (subdistribution hazard ratio, 0.92; 95% CI, 0.54-1.57; P = .78).
CONCLUSIONS AND RELEVANCE: In this randomized clinical trial of NSTEMI in frail older patients, there was no benefit to a routine invasive strategy in DAOH during the first year. Based on these findings, a policy of medical management and watchful observation is recommended for older patients with frailty and NSTEMI.
TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03208153.
参考来源
- Sanchis J, Bueno H, Miñana G, et al. Effect of Routine Invasive vs Conservative Strategy in Older Adults With Frailty and Non-ST-Segment Elevation Acute Myocardial Infarction: A Randomized Clinical Trial. JAMA Intern Med. 2023. PMID: 36877502. doi:10.1001/jamainternmed.2023.0047
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。